SOUTH KOREA — Samsung Biologics, a CDMO, has announced that it will construct a fifth plant in response to growing market demand. The new facility, which is part of the…
Read MoreSamsung Biologics invests in capacity expansion with fifth plant
Tag: Samsung Biologics
Pfizer partners with Samsung Bio for drug substance manufacturing until 2029
SOUTH KOREA — Samsung Biologics, a contract development and manufacturing organization (CDMO), has signed a biologics supply contract with pharma giant Pfizer worth KRW 241 billion (US$183 million) and it…
Read MoreSamsung Biologics reportedly pondering prospects in cell & gene therapy
SOUTH KOREA – Samsung Biologics CEO John Rim has said the South Korean biotech will explore the possibility of adding cell and gene therapy to its portfolio as it looks…
Read MoreSamsung Biologics grabs US$81M contract manufacturing deal with Novartis
SOUTH KOREA – Samsung Biologics and Novartis have signed an initial US$81 million contract manufacturing and development agreement, marking the first time the two companies have collaborated. Samsung Biologics disclosed…
Read MoreSamsung Biologics shells US$2.3 bln to complete acquisition of Samsung Bioepis
SOUTH KOREA – Samsung Biologics has completed the US$2.3 billion acquisition of Biogen’s stake in the Samsung Bioepis joint venture. Samsung Biologics signed a stake acquisition agreement in January of…
Read MoreSamsung Biologics buys out Biogen in biosim venture for US$2.3B
SOUTH KOREA – Samsung Biologics announced that it has agreed to pay US$2.3 billion for Biogen’s stake in their nearly decade-long biosimilars joint venture Samsung Bioepis. The announcement follows a…
Read MoreDemand surge for Covid-19 antibody prompts GSK, Vir to ramp up output
USA – To meet rising demand, GlaxoSmithKline and partner Vir Biotechnology are increasing output of their COVID-19 antibody treatment sotrovimab at a second plant. The supply crunch is exacerbated further…
Read MoreSamsung Biologics rolls out the supply of domestically-manufactured Moderna vaccines in South Korea
SOUTH KOREA – Samsung Biologics, a major South Korean contract drug manufacturer, has rolled out supplies of the first batch of domestically-made Moderna vaccines. Moderna’s COVID-19 vaccine, manufactured by Samsung…
Read More